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Abstract: Efficacy is the main objective of antiretroviral treatment and adherence is one of 
the cornerstones to achieve it. For this reason, treatment simplification is of key importance 
with regard to antiretroviral regimens. Rezolsta® (darunavir/cobicistat) is the first fixed-dose 
combination containing a protease inhibitor approved for HIV treatment. This coformulation 
includes darunavir, a protease inhibitor that has shown its efficacy and safety in naïve and 
treatment-experienced patients, and cobicistat, the new pharmacokinetic enhancer that is expected 
to replace ritonavir. Bioequivalence between ritonavir and cobicistat as darunavir boosters has 
been shown in studies involving healthy volunteers. Furthermore, efficacy and safety of darunavir/
cobicistat observed in phase III studies, including naïve and pretreated patients without darunavir-
associated resistance mutations, are comparable to historical data of darunavir/ritonavir 800/100 
mg once-daily formulation. Adverse events with darunavir/cobicistat are scarce and mild, and 
basically include skin reactions and gastrointestinal disturbances. Although small increases in 
plasma creatinine are expected in patients receiving cobicistat due to the inhibition of creatinine 
transporters in kidney tubules, actual glomerular filtrate rate remains unaltered. Cobicistat does 
not have an inducer effect on metabolic pathways and shows much more selective inhibition 
than ritonavir. Therefore, isoenzyms different from CYP3A4 are supposed to be less affected 
by cobicistat, and thus fewer drug–drug interactions are expected. 
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Introduction
Boosted darunavir is the preferred protease inhibitor (PI) for antiretroviral treatment 
(ART)-naïve patients that is recommended by most HIV guidelines worldwide.1,2  The 
efficacy of darunavir/ritonavir 800/100 mg once-daily formulation has been proved 
in many clinical trials in patients starting ART.3 Furthermore, darunavir/ritonavir 
once-daily regimen can also be used in ART-experienced patients with no darunavir 
resistance-associated mutations (RAMs).4 
Darunavir, as most PIs, is mainly metabolized through cytochrome P450 
(CYP3A4) in the liver and the gut.5 For this reason, coadministering a pharma-
cokinetic enhancer can increase plasma concentrations, allowing for once-daily 
administration and lower doses. So far, ritonavir, administered in low doses (100 mg 
once or twice daily), has been the only pharmacokinetic enhancer available in ART.6 
Ritonavir acts as a potent CYP3A4 and P-glycoprotein (P-gp) inhibitor, increasing 
the oral bioavailability of coadministered drugs. This pharmacokinetic enhance-
ment affects not only antiretroviral drugs such as PIs or elvitegravir, but also all 
other comedications metabolized through CYP that the patient might be receiving, 
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with the risk of drug–drug interactions and undesirable 
side effects. It is worth noting that even at boosting doses, 
ritonavir has activity against HIV, and if the patient is not 
receiving a fully active ART, there might be the possibility 
of developing resistance mutations to PIs.7
A new pharmacokinetic enhancer has become available 
to boost antiretroviral drugs. Cobicistat (GS-9350) was 
developed from the ritonavir molecule and thus has many 
similarities8 (Figure 1). It has been shown to increase plasma 
concentrations of atazanavir, darunavir, and elvitegravir.9–13 
Compared with ritonavir, cobicistat exhibits a more selec-
tive inhibition of CYP P450 system isoenzymes and does 
not have an inducing effect (of glucuronidation or CYP).8 
In addition, cobicistat can be coformulated in fixed-dose 
combinations (FDCs) due to its chemical stability and great 
aqueous solubility.8 However, cobicistat shows no intrinsic 
activity against HIV replication (Table 1). 
Recently, the combination of darunavir 800 mg with 
cobicistat 150 mg has been formulated in a FDC  (Rezolsta® 
[darunavir/cobicistat]; Janssen-Cilag, Beerse, Belgium)14 to 
improve convenience and adherence without loss of virological 
efficacy.15 This review analyzes the efficacy and safety of once-
daily darunavir/cobicistat FDC for the treatment of HIV/AIDS.
Efficacy and safety
The clinical safety and efficacy of cobicistat 150 mg as an 
enhancer for darunavir 800 mg once daily administered with 
a fully active backbone regimen of two nucleos(t)ide reverse 
transcriptase inhibitors (NRTIs) was evaluated in a single-arm, 
open-label, phase III clinical trial (GS-US-216-130).16 This 
study included 313 HIV-infected patients, 295 naïve and 18 
ART-experienced, without darunavir or NRTI RAMs in the 
baseline genotype, and the estimated glomerular filtration rate 
(eGFR) calculated by Cockcroft-Gault equation (eGFR
CG
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Figure 1 Chemical structures of ritonavir and cobicistat.
Table 1 Main differences between cobicistat and ritonavir
Characteristics Cobicistat Ritonavir
Capability of  
coformulation with  
other antiretrovirals
Good solubility
Coformulated with atazanavir, darunavir and  
tenofovir/emtricitabine/elvitegravir
Low solubility
Coformulated with lopinavir only
Inhibited metabolic pathways CYP3A4
CYP2D6
P-glycoprotein
OATP1B1/3
MATe1
BCRP
CYP3A4
CYP2D6
P-glycoprotein
OATP1B1/3
MATe1
BCRP
CYP2C8
CYP2C9
Induced metabolic pathways None CYP1A2
CYP2C19
CYP2C8
CYP2C9
CYP2B6
UGT1A4
Anti-HIV activity No Yes
Adverse effects Gastrointestinal disturbances
Lipid metabolism alterations
Skin reactions
Gastrointestinal disturbances
Lipid metabolism alterations
Insulin resistance
Renal function Not recommended for patients with impaired renal  
function (eGFRCG <70 mL/min) and taking 
tenofovir disoproxil fumarate
No restrictions
Abbreviations: eGFRCG, estimated glomerular filtration rate by Cockcroft-Gault equation; BCRP, breast cancer resistance protein; OATP, organic anion transporting 
polypeptides; MATE, multiantimicrobial extrusion protein; CYP, cytochrome P450; UGT, UDP-glucuronosyltransferase.
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≥80 mL/min. The patients were administered darunavir 800 
mg (2×400 mg tablets) plus cobicistat 150 mg (1 tablet) once 
daily with the NRTIs backbone selected by the investigator 
(tenofovir/emtricitabine in 96% of the patients). The overall 
virological suppression was 82% (258/313; 95% confidence 
interval [CI]: 78–87) at week 24 and 81% (253/313; 95% 
CI: 76–85) through week 48, irrespective of the baseline 
viral load below or above 100,000 copies/mL (81% and 80%, 
respectively).16 Within treatment-naïve patients, virological 
success was observed in 83% (244/295; 95% CI: 78–87) 
of the patients at week 48. These results are consistent with 
historical data from the ARTEMIS (naïve patients) and ODIN 
(experienced patients) trials with darunavir/ritonavir 800/100 
mg once-daily regimen.3,4
Tolerability and safety results of darunavir/cobicistat 
800/150 mg once-daily combination from this trial were in 
agreement with previous data reported regarding daruna-
vir and/or cobicistat. The majority of adverse events were 
mild, with gastrointestinal disturbances (diarrhea, nausea, 
flatulence). There were 21 (7%) grade 3 or 4 adverse events, 
mainly rash or other skin reactions, and 16 (5%) of them led 
to study-drug discontinuation.16 
The other clinical data come from a phase II random-
ized, double-blind, placebo-controlled trial (GS-US-299-
102) comparing darunavir/cobicistat (as single agents) 
plus tenofovir disoproxil/emtricitabine versus tenofovir 
alafenamide/ emtricitabine (in a single-tablet regimen [STR]) 
in 150 treatment-naïve HIV-1 infected patients.17 Virological 
response rate at week 48 was 84% in those patients random-
ized to receive darunavir/cobicistat plus tenofovir disoproxil/
emtricitabine and 77% in the STR arm. As in the GS-US-
216-130 study,16 drug discontinuations due to adverse events 
were scarce and occurred in four (2.6%) patients.
Although darunavir has been shown to exhibit in vitro 
activity against HIV-2 strains,18 data published in real-life 
setting are scarce and include patients receiving darunavir 
plus ritonavir containing regimens.19 Furthermore, there are 
no studies evaluating the efficacy of darunavir/cobicistat in 
HIV-2 infected patients. For this reason, this combination is 
only indicated for HIV-1 infection.14
Finally, there are no data regarding the use of darunavir/
cobicistat combination in pediatric or adolescent popula-
tions, thus its use is only recommended in adult patients 
aged above 18 years.14
Cobicistat and kidneys
Cobicistat is renally excreted through glomerular filtration 
and secreted by the proximal tubule. In vitro data have 
 demonstrated that cobicistat is a weak inhibitor of human 
renal transporters OCT2 and MATE2-K and a more potent 
inhibitor of OCTN1 and MATE1 than ritonavir.20 Thus, cre-
atinine secretion through MATE1 transporter in the apical 
side of the tubular cell is affected. For this reason, an increase 
of 0.05–0.1 mg/dL in plasma creatinine concentrations and a 
decrease of ~10 mL/min in eGFR
CG
 are expected at week 4 
after cobicistat is started. This variation remains stable during 
treatment with cobicistat and reverts once it is discontinued.21 
However, clearance remains unaffected20 when GFR is cal-
culated using standardized methods to assess actual (rather 
than estimated) clearance, such as iohexol, a substance not 
secreted or reabsorbed by renal tubule.22 However, this inhi-
bition does not affect proximal tubule secretion of tenofovir 
as it is excreted through different renal transporters, such as 
the organic anion transporter 1/3 and MRP4.21 
The GS-US-216-130 study analyzed the impact of cobici-
stat plus darunavir in patients with normal renal function.16 A 
median increase of 0.1 mg/dL in baseline plasma creatinine 
levels was observed at week 2 and remained stable through-
out week 48. Treatment discontinuation due to renal tubular 
disorder occurred in only one patient receiving tenofovir/
emtricitabine. This renal disturbance reverted after switching 
to darunavir/ritonavir plus abacavir/lamivudine. 
The effect of cobicistat plus darunavir in patients with 
mild-to-moderate renal impairment was analyzed in the 
GS-US-236-118 study.23 Patients with eGFR between 50 and 
89 mL/min receiving ritonavir-boosted atazanavir (n=52) or 
darunavir (n=21) based regimens (n=21) had ritonavir switched 
for cobicistat. Although eGFR
CG
 decreased to a greater extent 
in patients starting with eGFR >70 mL/min vs <70 mL/min 
(median [interquartile range], –7.6 [–15.2 to –3.6] mL/min vs 
–3.1 [–5.1 to 0.5] mL/min), no clinically relevant changes in 
cystatin C-based eGFR were seen through week 96 (–2.8 [–7.4 
to 8.9] mL/min). Notwithstanding, two patients interrupted the 
treatment with antiretroviral drugs (one due to abnormal eGFR 
and one due to hematuria/proteinuria). Other reported adverse 
events were grade 1 hypophosphatemia (one patient), grade 2 
proteinuria (one patient) and isolated increases of >0.4 mg/dL 
in serum creatinine levels (three patients), without any discon-
tinuations due to proximal renal tubulopathy.
Pharmacokinetic data
After oral administration of darunavir/cobicistat 800/150 mg, 
darunavir is rapidly absorbed achieving maximum plasma 
concentrations in 3–4.5 hours. This absorption is 1.7-fold 
higher if darunavir is administered with food compared to 
when fasting, and for this reason the prescribing  information 
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recommends taking darunavir/cobicistat in fed state.14,24 
Cobicistat binds in high proportion to plasma proteins 
(97%–98%), and a major portion of the drug is eliminated 
through the feces (86%) and a minimal amount through 
urinary excretion (8.2%).25 In healthy volunteers receiving 
doses of 100 and 200 mg/day of cobicistat, mean volume of 
distribution was 152 and 100 L, respectively.11 Cobicistat has 
a median plasma half-life of 3–4 hours.25 
The exposure to darunavir following darunavir/cobici-
stat 800/150 mg once daily either as single agents or FDC 
formulations (candidates GS003 and GS004 and final for-
mulation GS006) was comparable to exposure to darunavir/
ritonavir 800/100 mg once daily in two phase I clinical trials 
with healthy volunteers (Table 2).24,26 It is worth noting that 
an increase in end-of-dose (C
24 h
) darunavir concentration 
was seen when coadministered with ritonavir, and this late 
peak implied a 30% decrease of darunavir trough concen-
trations when coadministered with cobicistat compared to 
ritonavir.26 However, when given with cobicistat, darunavir 
trough concentrations were still 25 times above the protein-
binding-adjusted inhibitory concentration (IC
50
) for HIV-1 
strains without darunavir RAMs (55 ng/mL),27 and probably 
these differences may not be clinically significant in a real-
life setting. 
In 60 HIV-infected patients, pharmacokinetic profile of 
darunavir was analyzed by giving darunavir 800 mg plus 
cobicistat 150 mg as single agents once daily along with an 
optimized background regimen selected by the investigator.16 
Mean ± standard deviation darunavir AUC, C
max
 and C
trough
 
values were 81,646 ± 26,322 ng·h/mL, 7,663 ± 1,920 ng/mL, 
and 1,311 ± 969 ng/mL, respectively, which were comparable 
to the results obtained in healthy volunteers24,26 and exhibited 
no association between darunavir AUC or trough concentra-
tions and virologic response or safety.16
Drug–drug interactions with 
darunavir/cobicistat
As mentioned previously, cobicistat works as a pharmacokinetic 
enhancer mainly through CYP3A4 inhibition. However, cobi-
cistat also has a weak inhibitory activity on CYP2D6 and on 
other enzymes and transporters, especially P-gp in the liver and 
gut, solute carrier organic anion transporters (OATP) 1B1/3 in 
the liver, multidrug and toxin extrusion protein 1 (MATE1) in 
the kidney and breast cancer resistance protein (BCRP) in the 
gut.14,25 Cobicistat is metabolized by CYP3A and to a minor 
extent by CYP2D6 and does not undergo glucuronidation.25
Despite these similarities, there are still some differences 
between cobicistat and ritonavir. Cobicistat is a more selec-
tive CYP3A4 inhibitor and has no clinical effect on other 
isoenzymes inhibited by ritonavir (eg, 2C8 and 2C9).8,28 
Moreover, ritonavir shows in vivo induction activity on 
some CYP isoenzymes (eg, 1A2, 2C19, 2C8, 2C9, and 2B6), 
glucuronyl transferases (eg, UGT1A4), and P-gp.28 On the 
other hand, ritonavir also activates the pregnane X receptor 
(PXR), which regulates the expression of various drug-
metabolizing enzymes, including CYP3A. Thus, although 
the net effect of ritonavir over CYP3A4 is inhibition, it also 
exhibits a potential inducer effect on this CYP isoenzyme. 
On the contrary, cobicistat has no inducer effect on CYP, 
glucoronyl transferases or PXR.8
Table 2 Bioequivalence pharmacokinetic studies comparing darunavir boosted with ritonavir or with cobicistat either as single agents 
or in FDC with darunavir
Study Geometric mean ratio (90% CI)
AUC
(mg·h/L)
Cmax
(mg/L)
Ctrough
(mg/L)
Mathias et al10 DRV 800 mg qd + RTV 100 mg qd (n=31)
DRV 800 mg qd + COBI 150 mg qd (n=33)
1.02 (0.97–1.06) 1.03 (1.00–1.06) 0.69 (0.59–0.82)
Kakuda et al26 GS003
DRV 800 mg qd + RTV 100 mg qd (n=32)
DRV/COBI 800/150 mg qd (n=33)
0.97 (0.92–1.02) 0.97 (0.92–1.01) 0.69 (0.60–0.81)
GS004
DRV 800 mg qd + RTV 100 mg qd (n=32)
DRV/COBI 800/150 mg qd (n=33)
0.99 (0.94–1.04) 1.00 (0.96–1.04) 0.74 (0.63–0.86)
Kakuda et al24 Fasted conditions
DRV 800 mg qd + COBI 150 mg qd (n=72)  
DRV/COBI 800/150 mg qd (n=74)
0.96 (0.94–1.02) 0.99 (0.94–1.04) NR
Fed conditions
DRV 800 mg qd + COBI 150 mg qd (n=38)  
DRV/COBI 800/150 mg qd (n=40)
0.98 (0.93–1.03) 0.97 (0.93–1.01) NR
Abbreviations: FDC, fixed-drug combination; DRV, darunavir; RTV, ritonavir; COBI, cobicistat; NR, not reported; CI, confidence interval; qd, every day.
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Therefore, cobicistat has a greater selectivity for CYP3A4 
and lacks an induction effect. However, due to its mechanism 
of action, most of the interactions seen with ritonavir are 
likely to be observed with cobicistat. Nowadays, there are 
scarce data about drug–drug interactions with cobicistat as 
a PI enhancer, and most of the pharmacokinetic data about 
cobicistat are based on cobicistat/elvitegravir/tenofovir/
emtricitabine FDC studies. Indeed, no specific drug interac-
tion trials have been published with the FDC of darunavir/
cobicistat. For this reason, the potential interactions are 
assumed to be similar to those observed with darunavir/
ritonavir. Some of the most relevant drug interactions and 
contraindicated drugs with darunavir/cobicistat according 
to its prescribing information are summarized in Table 3.14
CYP3A4 is probably the most important metabolic 
pathway, but some drugs are metabolized through other 
CYP isoenzymes (CYP1A2, 2B6, 2C8, 2C9, and 2C19) or 
glucuronidation, which are affected by ritonavir but not by 
cobicistat.29 Thus, inferring ritonavir interactions to cobicistat 
is not always a good option. Examples include olanzapine 
(CYP1A2 and glucuronidation), acenocumarol (CYP2C9, 
1A2, and 2C19), propofol (CYP2B6 and glucuronidation), 
lamotrigine and valproate (CYP2C9 and glucuronidation), 
gliclazide (CYP2C9 and 2C19), and mycophenolate and 
gemfibrozil (glucuronidation).30 Caution should be taken 
when administering cobicistat with P-gp substrates, such as 
digoxin, as plasma levels of the substrate might be increased 
due to a boost in intestinal absorption leading to potential 
severe adverse events.31 Furthermore, those patients receiv-
ing adjusted doses of concomitant drugs because of ritonavir 
should be closely controlled during the first 2 weeks of the 
switch to cobicistat to detect possible changes in drug–drug 
interactions.14 Therefore, it is important to know the meta-
bolic pathways of coadministered drugs taken by patients 
receiving ritonavir prior to switching to cobicistat. 
As a substrate of CYP3A, plasma concentrations of cobi-
cistat are affected by inhibitors/inducers of this isoenzyme. 
Coadministration with other inhibitors will increase cobici-
stat concentrations, potentially leading to undesired effects 
and increased toxicity. On the contrary, CYP3A inducers 
Table 3 Drugs contraindicated or not recommended with darunavir/cobicistat and mechanism of interaction between drugs 
Drug class Drug within class Mechanism of interaction Coadministration 
recommendation 
Non-nucleoside reverse 
transcriptase inhibitors 
Efavirenza, nevirapinea, etravirinea Induction of CYP3A by NNRTI Not recommended 
Antianginal/ 
antiarrhythmic 
Amiodarone, bepridil, dronedarone,  
systemic lidocaine, quinidine, ranolazine 
Inhibition of CYP3A by COBI Contraindicated 
Anticoagulant/platelet  
aggregation inhibitor
Apixaban, dabigatran, rivaroxaban 
ticagrelor 
Inhibition of CYP3A/P-gp by COBI Not recommended 
(contraindicated 
with ticagrelor) 
Anticonvulsants Carbamazepine, phenobarbital, phenytoin Induction of CYP3A by anticonvulsants Contraindicated 
Antimycobacterials Rifampicin 
rifabutina 
rifapentine 
Induction of CYP3A by rifamycins Contraindicated 
with rifampicin and 
not recommended 
with rifabutin and 
rifapentine 
Anti-neoplastics Everolimus Inhibition of CYP3A by COBI Not recommended 
Antipsychotics/neuroleptics Pimozide, sertindole, quetiapine Inhibition of CYP2D6 by COBI Contraindicated 
Corticosteroids Budesonide, fluticasone Inhibition of CYP3A by COBI Not recommended 
endothelin receptor antagonists Bosentan Induction of CYP3A by bosentan Not recommended 
Direct-acting antivirals (HCV) Boceprevir, telaprevir, simeprevir Multidirectional interaction Not recommended 
HMG-CoA reductase inhibitors Lovastatin, simvastatin Inhibition of CYP3A by COBI Contraindicated 
Inhaled beta-agonists Salmeterol Inhibition of CYP3A by COBI Not recommended 
Phosphodiesterase 5 inhibitors Sildenafil (for pulmonary arterial  
hypertension), avanafil 
Inhibition of CYP3A by COBI Contraindicated 
Sedatives/hypnotics Oral midazolam, triazolam Inhibition of CYP3A by COBI Contraindicated 
ergot derivatives Dihydroergotamine, ergometrine, ergotamine Inhibition of CYP3A by COBI Contraindicated 
Herbal supplements Hypericum perforatum (St. John’s wort). Induction of CYP3A by Hypericum Contraindicated 
Notes: If CYP3A is inhibited by cobicistat, plasma concentrations of the coadministered drug increase, with the subsequent risk of greater toxicity. If CYP3A is induced by 
another drug, darunavir and/or cobicistat plasma concentrations decrease, with the subsequent risk of virological failure. aThe prescribing recommendations for these drugs 
differ between darunavir/cobicistat and darunavir/ritonavir. Reproduced from Rezolsta® [prescribing information]. Available from: http://www.ema.europa.eu/docs/en_GB/
document_library/EPAR_-_Product_Information/human/002819/WC500178953.pdf. Accessed August 19, 2016.14
Abbreviations: COBI, cobicistat; CYP, cytochrome P450; HMG-CoA, 3-hydroxy-3-methylglutaryl coenzyme A.
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could decrease cobicistat concentrations,  increasing the risk 
of virological failure. Some non-nucleoside reverse tran-
scriptase inhibitors (NNRTIs) such as etravirine, efavirenz or 
nevirapine can be potent inducers and their  coadministration 
with cobicistat is not recommended,14 which is a significant 
difference between using cobicistat and ritonavir as boosters. 
This can be relevant for some patients currently receiving 
a combination of darunavir/ritonavir and an NNRTI (eg, 
etravirine), who cannot automatically be switched to daruna-
vir/cobicistat. Another difference between cobicistat and 
ritonavir is their interaction with rifabutin. Although dose 
adjustments can be done to rifabutin, its coadministration 
with cobicistat is contraindicated.14 
Cobicistat is not suitable to boost PIs different from 
atazanavir or darunavir due to a lack of data.25 Furthermore, 
the combination of darunavir/cobicistat is not potent enough 
to enhance the activity of other coadministered drugs that 
need boosting, such as elvitegravir or other PIs, as this might 
involve a higher risk for subtherapeutic plasma levels and 
subsequent virological failure.14
Taking into consideration all the potential interactions 
and the constant availability of new information, access to 
updated information is one the most important things with 
regard to drug–drug interactions. For this reason, clinicians 
should consult specific sites, such as the Liverpool HIV drug 
interactions website,30 before prescribing new medications 
to patients receiving darunavir/cobicistat. 
Use of darunavir/cobicistat in the 
clinical practice
Ease of use is probably the strongest point of darunavir/
cobicistat FDC (less not only by one pill but also by one drug 
bottle) without losing efficacy and maintaining almost the 
same flexibility as ritonavir to combine with other antiretrovi-
ral drugs. Looking in the near future, an STR with darunavir/
cobicistat plus emtricitabine and tenofovir alafenamide will 
be the first STR based on a PI, due to the better solubility 
of cobicistat.8,32 
Currently, integrase inhibitors have become the preferred 
option in most of the ART guidelines due to their higher effi-
cacy and tolerability and better safety profile.1 NNRTIs and 
PIs have been relegated to alternative regimens.1 However, 
a PI-based treatment is still the preferred option in patients 
with poor adherence to treatment, in whom a high genetic-
barrier regimen is needed. When adherence is an issue, there 
is still discussion whether it is better to use a regimen based 
on a small number of pills (an STR if possible) or to use a 
high-barrier treatment based on a PI, despite associated with 
a higher burden of pills. In late presenters, with low CD4 cell 
count and/or opportunistic infections at the diagnosis of HIV 
infection, some physicians would prefer to start a PI-based 
treatment while waiting to confirm adherence and the results 
of baseline resistance tests. The darunavir/cobicistat FDC 
simplifies the regimen in these groups of patients, reduces 
the risk of prescription errors and eliminates the risk of 
selective nonadherence.
In a time of economic constraints, darunavir/cobicistat 
combination could improve convenience in less expensive 
regimens and help in maintaining good tolerability.33 Keeping 
in mind that salvage regimens are mainly based on the use 
of PIs and that darunavir/cobicistat can be used in patients 
without darunavir RAMs, rescue regimens with a low burden 
of pills and once-daily posology are now a reality.3 Further-
more, in an attempt to avoid long-term toxicities related to 
the use of some NRTIs, there have been some studies that 
have shown a great efficacy with a dual therapy combining 
a boosted PI plus lamivudine as a simplification strategy,34,35 
although with ritonavir as the booster. Finally, darunavir/
cobicistat FDC could become a STR treatment in the selected 
group of patients receiving a PI monotherapy. 
However, the use of a booster is associated with some 
disadvantages. Although cobicistat has a more selective 
 inhibitory activity, drug interactions are similar to those 
observed with ritonavir given that CYP3A is the most 
important human metabolic pathway for the majority of 
the drugs. Taking into account that HIV-infected patients 
are getting older and polypharmacy is a reality, the lower 
risk of off-target interactions could be a favorable aspect 
for cobicistat. 
Tolerability profile is similar to that observed with ritona-
vir and only gastrointestinal and lipid disturbances seem to be 
a problem in a small percentage of the patients.8,26,33 Neverthe-
less, cobicistat seems to have a more “metabolic-friendly” 
profile, as it has shown no effect on lipid accumulation in 
adipocytes and displays less insulin resistance than ritonavir 
in in vitro studies.8 However, more data and a longer follow-
up period are necessary to determine whether cobicistat has 
better long-term toxicity profile and tolerability benefits as 
compared with ritonavir.
It is worth noting that cobicistat inhibits tubular creatinine 
secretion, which disturbs renal function estimation without 
affecting the real glomerular function.21 However, there are 
several other antiretroviral drugs with a similar effect, such 
as ritonavir, rilpivirine and dolutegravir, which may also 
increase plasma creatinine levels due to MATE1 inhibition 
in the renal tubular cell.36 Furthermore, there is enough data 
in clinical trials to consider cobicistat as a safe option in 
patients with impaired renal function.20,37 
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Conclusion
Darunavir/cobicistat FDC is an effective, well tolerated and 
simpler option to treat HIV-infected patients. It is expected 
to improve adherence and might avoid some of the drug 
interactions observed with ritonavir. Furthermore, the STR 
with darunavir/cobicistat plus emtricitabine and tenofovir 
alafenamide will probably be the one-pill regimen with the 
highest genetic barrier till date.
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